RPE65 and proximal spinal muscular atrophy: High-profile approvals of gene therapies for pediatric-onset diseases like spinal muscular atrophy and RPE65-related retinal disease could potentially pave the way for gene therapies as a model for both therapeutic and market viability [36, 37].